Amyloid β-Protein (Human, 1-38)
Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly (Trifluoroacetate Form)
4484-v 0.5 mg | 135.00 EUR
| (M.W. 4131.5) | C184H277N51O56S | [131438-74-9] |
Synthetic Product
Purity minimum 95.0 % per HPLC (according Data Sheet)
Endogenous Form of Amyloid β-Protein in Cerebrospinal Fluid
References:
- M.P. Mattson, B. Cheng, D. Davis, K. Bryant, I. Lieberburg and R.E. Rydel, J. Neurosci., 12, 376 (1992). (Pharmacol.; Enhancement of Glutamate Neurotoxicity)
- J.M. Maler, H.W. Klafki, S. Paul, P. Spitzer, T.W. Groemer, A.W. Henkel, H. Esselmann, P. Lewczuk and J. Wiltfang, Proteomics, 7, 3815 (2007). (Quantitation in Human Plasma)
- M.E. Lame, E.E. Chambers and M. Blatnik, Anal. Biochem., 419, 133 (2011). (Quantitation in Human Cerebrospinal Fluid)
